https://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deathsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deathshttps://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deaths#u57321Fri, 04 Sep 2026 20:45:15 +0000Novartis suspended eight clinical trials of its rap-cel CAR-T therapy after three patients died from immune effector cell-associated hemophagocytic syndrome (IEC-HS). This rare complication occurs during the treatment of neurological and autoimmune diseases such as rheumatoid arthritis and lupus. Bristol Myers Squibb also paused its Zola-cel trials for autoimmune disorders as a precaution. Both companies have notified regulators and researchers of these safety reviews to address severe immune reactions and inflammatory events.Why it mattersCAR-T therapies engineer a patient's own immune c https://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deathshttps://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deaths#u55573Thu, 03 Sep 2026 11:17:10 +0000Novartis has suspended eight clinical trials of its CD19-directed CAR-T therapy, rapcabtagene autoleucel (rap-cel), following three patient deaths caused by severe immune reactions. Bristol Myers Squibb also voluntarily paused enrollment in its Zola-cel autoimmune studies due to transient inflammatory events. Both companies informed Endpoints News of these safety reviews. Wall Street analysts suggest that stricter manufacturing, enrollment protocols, and side effect management are necessary to prevent future safety hazards in the development of cell therapies for autoimmune conditions.Why it m https://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deathshttps://www.live-feeds.com/feed/novartis-pauses-autoimmune-cell-therapy-studies-after-deaths#u54277Wed, 02 Sep 2026 02:55:10 +0000Novartis suspended eight cell therapy trials, including immunology and neurology studies, after three patients died from immune effector cell-associated hemophagocytic syndrome. This condition occurs when the immune system overreacts and attacks its own organs. Bristol Myers Squibb also paused some CAR-T trials, citing separate observations of transient and reversible inflammatory events. Both companies halted their respective programs due to these safety concerns regarding experimental cell therapies designed to treat autoimmune conditions.Why it mattersCAR-T therapy traditionally treats canc